Viking Therapeutics, Inc. (VKTX)
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
Address
9920 PACIFIC HEIGHTS BLVD, SUITE 350
SAN DIEGO, CA 92121
Founded
2012
Number of Employees
27
Buyback
| Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $ Amount Purchased ($ in 000s) |
- | $418 | $31 | $22 | $127 | $151 | $295 | $707 | $7,276 | - | - | $1,129 |
| Average Price | - | $9.49 | $1.29 | $1.73 | $4.89 | $8.55 | $6.71 | $6.04 | $3.17 | - | - | $3.49 |
| # Shares Purchased | - | 44,093 | 24,165 | 12,534 | 26,006 | 17,709 | 44,042 | 117,025 | 2,298,726 | - | - | 323,038 |
| Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Return to Date | - | 595.5% | 5,022.7% | 3,708.5% | 1,251.1% | 671.9% | 883.8% | 992.2% | 1,985.1% | - | - | 1,789.1% |
| S&P 500 Return to Date | - | 173.0% | 168.6% | 129.7% | 104.9% | 93.1% | 74.8% | 31.7% | 37.3% | - | - | 101.6% |
| Excess Total Return | - | 422.5% | 4,854.1% | 3,578.8% | 1,146.2% | 578.8% | 808.9% | 960.5% | 1,947.8% | - | - | 1,687.5% |
| Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
| Percentile Rank | - | 95% | 100% | 100% | 99% | 98% | 98% | 100% | 100% | - | - | 100% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
Never miss an email alert when insiders at VKTX make a trade.
Creating a free account takes less than one minute